Lodine (etodolac)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved July 1996

Specific Treatments:

rheumatoid arthritis

Find Related Trials for The Following Conditions

General Information

Lodine has been approved for the treatment of rheumatoid arthritis. Lodine is a nonsteroidal anti-inflammatory drug (NSAID).

At the same time the FDA has cleared for market a new 500 mg dosage strength.

Clinical Results

The safety and efficacy of Lodine in relieving the signs and symptoms of rheumatoid arthritis were established in a three-year, double-blind, multicenter clinical trial involving 1,446 subjects with active rheumatoid arthritis. Data from the study indicated that doses of Lodine at 1,000 mg/day were efficacious and well tolerated in subjects being treated for active rheumatoid arthritis.

Literature References

Lanza F, Rack MF, Lynn M et al. "An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa." J Rheumatology 1987; 14:338-341.